ReviewCancers2021
Targeting
Review in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed.
- Beyond KRASG12C: emerging therapeutic strategies, patent landscape, and clinical progress in targeting KRAS-mutant cancers.Medical oncology (Northwood, London, England) · 2026Review
- Immunohistochemical analysis and scRNA-Seq identifies vascular endothelial CXCR4 expression as a predictor of poor prognosis in pancreatic ductal adenocarcinoma.Translational oncology · 2026Article
- AdultHemaSphere · 2026Article
- Article
- Targeting KRAS mutations: orchestrating cancer evolution and therapeutic challenges.Signal transduction and targeted therapy · 2025Review
- Cannabidiol sensitizes triple-negative breast cancer cells to NK cell-mediated killing via EGFR inhibition and FAS upregulation.Journal of cannabis research · 2025Article
- Focused Structure-Based Virtual Screening Identifies Novel Inhibitors of SOS1.ACS medicinal chemistry letters · 2025Article
- Inverted chimeric RNAi molecules synergistically cotarget MYC and KRAS in KRAS-driven cancers.The Journal of clinical investigation · 2025Article
- SLAMF8 expression and prognostic significance in melanoma: A multi-omics and Mendelian randomization study.Cancer biomarkers : section A of Disease markers · 2025Article
- Review
- Review
- Tissue-based genomic profiling of 300,000 tumors highlights the detection of variants with low allele fraction.NPJ precision oncology · 2025Article
- Review
- Article
- CPA4 overexpression correlates with poor prognosis and tumor progression in endometrial cancer.European journal of medical research · 2025Article
- Selenium Nanoparticles Synergize with a KRAS Nanovaccine against Breast Cancer.Advanced healthcare materials · 2025Article
- Targeting KRAS: from metabolic regulation to cancer treatment.Molecular cancer · 2025Review
- Clinical Progress of Targeted Therapy for Breast Cancer: A Comprehensive Review.Current cancer drug targets · 2025Review
- Mitochondrial micro RNAs: Crucial players in carcinogenesis.Oncology research · 2025Review
- Anticancer Potential of Pineapple and its Bioactive Compound Bromelain.Current pharmaceutical design · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The Kirsten rat sarcoma viral oncogene homolog (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.